Prothena Corp. (NASDAQ:PRTA)’s share price was up 1.7% during trading on Thursday . The stock traded as high as $41.48 and last traded at $41.25, with a volume of 218,554 shares changing hands. The stock had previously closed at $40.55.

Several equities analysts have commented on PRTA shares. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Wednesday, June 22nd. Zacks Investment Research raised Prothena Corp. from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. Barclays PLC started coverage on Prothena Corp. in a report on Friday, May 13th. They issued an “overweight” rating and a $60.00 price target for the company. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Friday, June 10th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Prothena Corp. in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $74.60.

The stock has a 50-day moving average price of $43.14 and a 200 day moving average price of $43.03. The company’s market capitalization is $1.43 billion.

Prothena Corp. (NASDAQ:PRTA) last released its earnings results on Tuesday, May 3rd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.04. Equities analysts predict that Prothena Corp. will post ($3.72) earnings per share for the current year.

In other news, Director Dennis J. Selkoe sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the completion of the sale, the director now owns 3,025 shares in the company, valued at $136,125. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Karin L. Walker sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $45.11, for a total value of $180,440.00. Following the sale, the insider now owns 2,000 shares of the company’s stock, valued at approximately $90,220. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System increased its stake in Prothena Corp. by 4.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,358 shares of the company’s stock worth $1,182,000 after buying an additional 803 shares during the last quarter. Nationwide Fund Advisors increased its stake in Prothena Corp. by 77.8% in the fourth quarter. Nationwide Fund Advisors now owns 35,835 shares of the company’s stock worth $2,441,000 after buying an additional 15,683 shares during the last quarter. California State Teachers Retirement System increased its stake in Prothena Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 57,940 shares of the company’s stock worth $3,946,000 after buying an additional 900 shares during the last quarter. American Century Companies Inc. increased its stake in Prothena Corp. by 36.8% in the fourth quarter. American Century Companies Inc. now owns 41,054 shares of the company’s stock worth $2,796,000 after buying an additional 11,043 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Prothena Corp. by 7.5% in the fourth quarter. Rhumbline Advisers now owns 30,805 shares of the company’s stock worth $2,098,000 after buying an additional 2,140 shares during the last quarter.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.